Latest Insider Transactions at Axogen, Inc. (AXGN)
This section provides a real-time view of insider transactions for Axogen, Inc. (AXGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Axogen, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Axogen, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2021
|
Guido J Neels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,173
+11.24%
|
-
|
|
Jun 01
2021
|
Quentin S. Blackford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,173
+20.26%
|
-
|
|
Jun 01
2021
|
Amy Mc Bride Wendell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,173
+16.13%
|
-
|
|
Jun 01
2021
|
Mark Stephen Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,173
+2.0%
|
-
|
|
May 26
2021
|
Gregory Gene Freitag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
102,954
+6.42%
|
$514,770
$5.72 P/Share
|
|
May 19
2021
|
Guido J Neels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+36.79%
|
$160,000
$4.45 P/Share
|
|
Apr 28
2021
|
Erick Wayne De Vinney Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.35%
|
$20,000
$2.86 P/Share
|
|
Apr 16
2021
|
Karen L. Zaderej CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+11.55%
|
$500,000
$5.09 P/Share
|
|
Mar 25
2021
|
Karen L. Zaderej CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,500
+4.93%
|
$103,500
$3.67 P/Share
|
|
Feb 25
2021
|
Gregory Gene Freitag Director |
SELL
Open market or private sale
|
Direct |
24,000
-9.51%
|
$528,000
$22.06 P/Share
|
|
Feb 18
2021
|
Michael Patrick Donovan VP Operations |
SELL
Open market or private sale
|
Direct |
1,808
-4.24%
|
$34,352
$19.15 P/Share
|
|
Feb 17
2021
|
Isabelle Billet Chief Strategy and BD Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
454
-3.94%
|
$8,172
$18.71 P/Share
|
|
Feb 17
2021
|
Karen L. Zaderej CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,686
-0.61%
|
$138,348
$18.71 P/Share
|
|
Feb 17
2021
|
Peter J Mariani EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,954
-8.08%
|
$53,172
$18.71 P/Share
|
|
Feb 17
2021
|
Maria D. Martinez Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
406
-6.78%
|
$7,308
$18.71 P/Share
|
|
Feb 17
2021
|
Gregory Gene Freitag Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,577
-0.31%
|
$28,386
$18.7 P/Share
|
|
Feb 17
2021
|
Michael Patrick Donovan VP Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
797
-0.93%
|
$14,346
$18.71 P/Share
|
|
Feb 17
2021
|
Eric Sandberg Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
903
-21.89%
|
$16,254
$18.7 P/Share
|
|
Feb 17
2021
|
Erick Wayne De Vinney Chief Innovation Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,864
-1.36%
|
$33,552
$18.7 P/Share
|
|
Feb 17
2021
|
Mark Louis Friedman VP Regulatory Affairs & Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
951
-3.41%
|
$17,118
$18.71 P/Share
|
|
Feb 17
2021
|
Angelo Scopelianos Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
406
-5.45%
|
$7,308
$18.71 P/Share
|
|
Feb 16
2021
|
Isabelle Billet Chief Strategy and BD Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,325
+10.3%
|
-
|
|
Feb 16
2021
|
Karen L. Zaderej CEO |
BUY
Grant, award, or other acquisition
|
Direct |
29,999
+2.33%
|
-
|
|
Feb 16
2021
|
Peter J Mariani EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,812
+22.02%
|
-
|
|
Feb 16
2021
|
Maria D. Martinez Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,325
+18.11%
|
-
|
|
Feb 16
2021
|
Gregory Gene Freitag Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,161
+1.01%
|
-
|
|
Feb 16
2021
|
Michael Patrick Donovan VP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
2,605
+2.93%
|
-
|
|
Feb 16
2021
|
Eric Sandberg Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,531
+38.02%
|
-
|
|
Feb 16
2021
|
Erick Wayne De Vinney Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,231
+4.27%
|
-
|
|
Feb 16
2021
|
Mark Louis Friedman VP Regulatory Affairs & Policy |
BUY
Grant, award, or other acquisition
|
Direct |
3,111
+9.99%
|
-
|
|
Feb 16
2021
|
Angelo Scopelianos Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,325
+15.1%
|
-
|
|
Feb 05
2021
|
Michael Patrick Donovan VP Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
5,190
-11.28%
|
$98,610
$19.81 P/Share
|
|
Feb 05
2021
|
Michael Patrick Donovan VP Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.29%
|
$100,000
$5.14 P/Share
|
|
Jan 08
2021
|
Karen L. Zaderej CEO |
SELL
Open market or private sale
|
Direct |
65,000
-9.64%
|
$1,300,000
$20.0 P/Share
|
|
Dec 30
2020
|
Michael Patrick Donovan VP Operations |
SELL
Open market or private sale
|
Direct |
1,733
-6.24%
|
$29,461
$17.48 P/Share
|
|
Dec 29
2020
|
Isabelle Billet Chief Strategy and BD Officer |
SELL
Open market or private sale
|
Direct |
649
-6.4%
|
$11,033
$17.81 P/Share
|
|
Dec 29
2020
|
Maria D. Martinez Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
567
-10.84%
|
$9,639
$17.81 P/Share
|
|
Dec 29
2020
|
Mark Louis Friedman VP Regulatory Affairs & Policy |
SELL
Open market or private sale
|
Direct |
567
-4.85%
|
$9,639
$17.81 P/Share
|
|
Dec 29
2020
|
Karen L. Zaderej CEO |
SELL
Open market or private sale
|
Direct |
3,500
-0.52%
|
$59,500
$17.81 P/Share
|
|
Dec 29
2020
|
Angelo Scopelianos Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
567
-9.3%
|
$9,639
$17.81 P/Share
|
|
Dec 29
2020
|
Peter J Mariani EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,293
-11.08%
|
$21,981
$17.81 P/Share
|
|
Dec 29
2020
|
Gregory Gene Freitag Director |
SELL
Open market or private sale
|
Direct |
916
-0.37%
|
$15,572
$17.81 P/Share
|
|
Dec 29
2020
|
Michael Patrick Donovan VP Operations |
SELL
Open market or private sale
|
Direct |
567
-2.0%
|
$9,639
$17.81 P/Share
|
|
Dec 29
2020
|
Erick Wayne De Vinney Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
371
-0.58%
|
$6,307
$17.81 P/Share
|
|
Dec 27
2020
|
Isabelle Billet Chief Strategy and BD Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+18.48%
|
-
|
|
Dec 27
2020
|
Maria D. Martinez Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+30.54%
|
-
|
|
Dec 27
2020
|
Mark Louis Friedman VP Regulatory Affairs & Policy |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+16.44%
|
-
|
|
Dec 27
2020
|
Karen L. Zaderej CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,800
+1.28%
|
-
|
|
Dec 27
2020
|
Angelo Scopelianos Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+27.39%
|
-
|
|
Dec 27
2020
|
Peter J Mariani EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+31.03%
|
-
|